1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Acelyrin PsA Data Are Positive, But Is Its IL-17 Blocker Competitive?

 
• By Joseph Haas

Troubled since a miss in hidradenitis suppurativa last fall, Acelyrin’s izokibep succeeded in a psoriatic arthritis trial, but will the drug compete well against other IL-17 inhibitors?

Psoriatic arthritis
Acelryin hopes izokibep will be competitive in the PsA space • Source: Shutterstock

After disappointing its shareholders with Phase IIb/III data for IL-17a inhibitor izokibep in hidradenitis suppurativa (HS) last September, Acelyrin, Inc. reported Phase IIb/III data for the drug in psoriatic arthritis on 11 March that it claims will be competitive in that space, including a potential safety edge compared to a pair of investigational IL-17a/f inhibitors. Investors appeared to agree with the sentiment on 11 March, but at least one analyst said the PsA data do not look competitive.

Key Takeaways

  • Acelyrin hits its primary endpoint with izokibep in a Phase IIb/III study in psoriatic arthritis.

  • An IL-17a inhibitor, izokibep may compete with Cosentyx and Taltz in PsA and other dermatology conditions, as well as IL-17a/f inhibitors from UCB and MoonLake

In PsA, Acelyrin is eyeing both current and potential future competition, as Novartis AG’s Cosentyx (secukinumab) and Eli Lilly and Company’s Taltz (ixekizumab) are established IL-17 blockers in the indication, while UCB S.A. plans to file its psoriasis drug Bimzelx (bimekizumab) for approval at the US Food and Drug Administration this year for PsA, and MoonLake Immunotherapeutics AG is preparing to take sonelokimab into Phase III in the indication soon. (Also see "UCB Buoyant As Bimzelx Starts To Deliver" - Scrip, 29 February, 2024

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.